Following propensity score matching, there were no significant differences in any of the listed parameters, including age, sex, Cr, Na, AST, ALT, albumin, HBV-DNA levels, INR, baseline decompensation status (esophageal varices (EV)/gastric varices (GV) bleeding, ascites, hepatic encephalopathy, and hepatorenal syndrome), clinical index (MELD score and ALBI score), CCI, and cumulative duration of medication (ASMD < 0.1 indicates no significant difference between the two groups). This evidence concerns the gene GPT and esophageal varices.